Investing.com – Stocks Modern (NASDAQ:) and CureVac (NASDAQ:CVAC) are rising in pre-market trading on Tuesday as seasonal flu cases in the United States show a marked enhance. Moderna shares rose 3.4% and CureVac rose 5%, extending yesterday’s gains.
The upward trend in the share prices of these biotechnology companies is due to greater profits in the vaccine sector, including: Novavax (NASDAQ:) and BioNTech (NASDAQ:) also rose 7.3% and 1.2%, respectively. This enhance follows recent updates from the Centers for Disease Control and Prevention (CDC), which reported a edged enhance in influenza cases across much of the country, with significant increases in both A(H1N1)pdm09 and A(H3N2) influenza viruses.
The latest CDC data shows a disturbing trend: 18.7% of clinical laboratory tests came back positive for influenza, an enhance from the previous week. The number of outpatient visits for respiratory diseases also increased to 6.8%, remaining above the national baseline for the fifth consecutive week.
In addition to the impact of seasonal flu, the first recorded bird flu death in the United States, confirmed by the Louisiana Department of Health, caught market attention. A person over the age of 65 with pre-existing conditions contracted the virus through contact with non-commercial home stock and wild birds.
The CDC reiterated its recommendation for annual flu vaccination for all people 6 months of age and older and emphasized the importance of timely antiviral treatment, especially for people at increased risk of severe illness. With at least 5.3 million cases of flu, 63,000 hospitalizations and 2,700 deaths attributed to flu this season, the health agency is closely monitoring the flu along with other respiratory viruses, including Covid-19 and RSV.
Investors appear to be responding to the increased demand for vaccines and treatments resulting from increased flu activity, which is likely to continue as the season progresses. The market response to these changes reflects the critical role that vaccine developers play in public health, especially during periods of increased disease incidence.
This article was generated with the assistance of AI and reviewed by an editor. More information can be found in our Regulations.
